Docoh
Loading...

MDXG Mimedx

Filed: 30 Oct 20, 5:28pm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________

FORM 8-K
____________________

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 30, 2020
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
Florida001-3588726-2792552
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)

1775 West Oak Commons Ct., NE, Marietta GA 30062
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 651-9100
____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange
on which registered
Nonen/an/a

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐













Item 7.01 Regulation FD Disclosure.

On October 30, 2020, MiMedx Group Inc., (the "Company")issued a press release announcing that The Nasdaq Stock Market LLC approved its application for listing the Company's common stock on the Nasdaq Stock Market. A copy of the press release is attached hereto as exhibit 99.1 and is incorporated herein by reference.

It is expected that the Company's common stock will begin trading on the Nasdaq Stock Market at the opening of trading on or before November 5, 2020 under the symbol "MDXG".

Also on October 30, 2020, Timothy R. Wright, Chief Executive Officer of the Company published a letter to shareholders which discusses the Company's relisting on Nasdaq, having distributed its 2 millionth allograft, and future Company objectives. A copy of the letter to shareholders is attached hereto as Exhibit 99.2 and is incorporated herein for reference.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description of Exhibit
99.1
99.2
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.


SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MIMEDX GROUP, INC.
Date: October 30, 2020By:/s/ Peter M. Carlson
Peter M. Carlson
Chief Financial Officer